New Portfolio Company - Tarsis Technology Limited
RNS REACH
AIM: FIPP
7 December 2016
Frontier IP Group Plc
("Frontier IP" or the "Group")
New Portfolio Company - Tarsis Technology Limited
Frontier IP, which specialises in the commercialisation of intellectual property, is pleased to announce that it has received a 20 per cent. stake in Tarsis Technology Limited ("Tarsis"), the Group's third spin-out from the Department of Chemical Engineering and Biotechnology at the University of Cambridge.
Tarsis plans to develop and commercialise technology created by Dr. David Fairen-Jimenez, a Royal Society University Research Fellow at the Department of Chemical Engineering and Biotechnology at the University of Cambridge, and his research team. The technology allows slower and more controlled delivery of drugs using metal-organic frameworks (MOFs). The pharmaceutical industry has demonstrated early interest in the technology.
Frontier IP's role will be to provide commercialisation services and in-depth pharmaceutical industry expertise. Dr. Campbell Wilson, a non-executive director of Frontier IP, has been appointed as a non-executive director of Tarsis. Dr. Wilson is currently a member (and past chairman) of the Board of the UK Pharmaceutical Licensing Group and has worked in the pharmaceutical industry for over 35 years.
Dr. Campbell Wilson, Non- Executive Director of Frontier IP and Director of Tarsis, said:
"We are looking forward to working with Dr. Fairen-Jimenez on this promising opportunity. Frontier IP brings experience in commercialising IP and relationships with key players in relevant markets. Dr. Fairen-Jimenez's technology approach combined with our support and network in the pharmaceutical space can help accelerate the commercialisation for this exciting technology."
Dr. David Fairen-Jimenez, Chief Executive of Tarsis, said:
"This is a great opportunity to see the state-of-the-art materials we prepare in our labs move into the market. The synergy between Frontier IP and their experience in new ventures and in the pharmaceutical industry combined with our leading work in advanced materials for drug delivery will give a strong commercial dimension to this project."
ENDS
Enquiries
|
Frontier IP Group Plc |
|
T: 0131 240 1251 |
|
Neil Crabb, Chief Executive |
|
|
|
|
|
|
|
Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker) |
|
T: 020 7894 7000 |
|
David Foreman, Catherine Leftley, Corporate Finance |
|
|
|
David Banks, Sales |
|
|
|
|
|
|
|
Peterhouse Corporate Finance Limited (Joint Broker) |
|
T: 020 7469 0935 |
|
Lucy Williams |
|
|
|
|
|
|
|
Kreab (Financial PR) |
|
T: 020 7074 1800 |
|
Robert Speed, Matthew Jervois |
|
|
Notes to Editor:
About Frontier IP Group plc
Frontier IP specialises in assisting institutions and companies in the commercialisation and exploitation of their intellectual property. It establishes formal and informal relationships with sources of exploitable IP, principally universities. Its core business is building and growing a portfolio of equity stakes in spin-out companies by taking an active involvement in the commercialisation and funding of these businesses.
This information is provided by RNS
Latest directors dealings
- 7 hours ago Johnson Matthey
- 9 hours ago Galliford Try
- 9 hours ago Galliford Try
- 9 hours ago Centrica
- 10 hours ago Smith & Nephew